<DOC>
	<DOCNO>NCT00410410</DOCNO>
	<brief_summary>The purpose clinical research study learn abatacept improve sign symptom active ulcerative colitis patient adequate response therapy . The safety treatment also study</brief_summary>
	<brief_title>A Study Abatacept Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description>The Induction Period First Cohort ( IP1C ) arm ( 30/10 mg/kg 10 mg/kg ) placebo-controlled arm use primary endpoint analysis . The Induction Period Second Cohort arm ( IP2C 30/10 mg/kg 10 mg/kg ) placebo-controlled , sole purpose provide sufficient number participant maintenance phase . The first cohort ( IP1C ) randomize receive placebo 1 3 dos abatacept . Following completion IP1C randomization , second cohort ( IP2C ) randomize receive 1 2 dos abatacept . After participant IP1C complete discontinue , data lock formal analysis Induction Period primary endpoint perform . Summary table second cohort ( IP2C ) Maintenance Open-label phase generate second , subsequent data lock .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men woman 18 year older Ulcerative colitis lease 3 month Moderate severe active ulcerative colitis Inadequate response intolerance standard ulcerative colitis treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>